April 1, 2015 — iCAD Inc. researchers presented three e-posters highlighting results of up to four years of follow-up with the Xoft Axxent electronic brachytherapy (eBx) system at The American Academy of Dermatology 73rd Annual Meeting in San Francisco. The Xoft System is used in the treatment of non-melanoma skin cancer (NMSC).
The E-posters that were presented at the meeting included:
- “Electronic Brachytherapy for Non-Melanomatous Skin Cancer: Report of First 565 Lesions,” presented by Stephen Doggett, M.D., Aegis Oncology LLC
- “Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results up to 4 Years,” presented by Ajay Bhatnagar, M.D., MBA, 21st Century Oncology of Arizona
- “Initial Experience of Electronic Brachytherapy for the Treatment of 508 Non-melanoma Skin Cancer (NMSC) Lesions in 305 Patients,” presented by Robert Strimling, M.D., FAAD and Camtu Lee Jones
“Study results suggest that electronic brachytherapy is an effective treatment for patients with non-melanoma skin cancer, with few recurrences or side effects and excellent cosmetic results,” said Bhatnagar. “The studies support the use of the Xoft System for patients with non-melanoma skin cancer who are not candidates for surgical excision or traditional radiation therapy.”
At the meeting, iCAD also showcased its new comprehensive solution for clinical practices interested in implementing a skin electronic brachytherapy program. Comprised of the medical device, software, management services and support, Xoft Skin eBx offers a scalable and modular program that enables radiation oncology supervision with the necessary components to successfully incorporate a skin eBx program into any dermatology practice.
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment.
For more information: www.icadmed.com
August 09, 2024 
